Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (242)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 8, pp. 923-926

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study

    Liver International, Vol. 35, Núm. 2, pp. 417-421

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  2. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2013

  1. Faldaprevir and deleobuvir for HCV genotype 1 infection

    New England Journal of Medicine, Vol. 369, Núm. 7, pp. 630-639

  2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2011

  1. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

2010

  1. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy

    Antiviral Therapy, Vol. 15, Núm. 6, pp. 881-886

  2. Survival of HIV-infected patients with compensated liver cirrhosis

    AIDS, Vol. 24, Núm. 5, pp. 745-753

2009

  1. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

2008

  1. Optimal use of maraviroc in clinical practice

    AIDS, Vol. 22, Núm. 17, pp. 2231-2240

2007

  1. Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression

    Virus Genes, Vol. 34, Núm. 2, pp. 111-116

  2. Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the NucliSens EasyQ assay (version 1.1)

    Journal of Clinical Microbiology, Vol. 45, Núm. 1, pp. 88-92

2006

  1. HIV and HCV coinfection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 5, pp. 335-346

2005

  1. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management

    Drug Safety, Vol. 28, Núm. 1, pp. 53-66

  2. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT

    Journal of Clinical Microbiology, Vol. 43, Núm. 8, pp. 3860-3868